Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Abstract: A method and apparatus for manufacturing an equiaxed crystal aluminum alloy cast ingot by using additive manufacturing and rapid solidification techniques are provided. The apparatus comprises: a metal heating mechanism and a negative pressure cooling mechanism. The metal heating mechanism is located above the negative pressure cooling mechanism and is connected thereto by a nozzle. The negative pressure cooling mechanism comprises a vacuum chamber having an air inlet hole and an air outlet hole, and a three-dimensional moving ingot mechanism disposed inside the vacuum chamber. The three-dimensional moving ingot mechanism comprises a moving ingot and a two-dimensional moving platform vertically connected to the moving ingot. A water cooling mechanism is disposed outside the moving ingot, and the moving ingot is driven by a precision motor to precisely move up and down.

Abstract: Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

Abstract: Described herein are MK2 inhibitors of Formula (II) and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

Abstract: A refrigerant amount monitoring and charging control system for an electric vehicle and a method thereof include: a controller; a battery management module electrically connected to the controller; a high-speed charging gun connected to the vehicle when the vehicle is charged and configured to generate a high-speed charging signal during performing high-speed charging and to send the high-speed charging signal to the controller; an ambient temperature sensor electrically connected to the controller and configured to obtain an ambient temperature and to send the obtained ambient temperature to the controller; and a chiller including an electronic expansion valve and an evaporator. A situation where a vehicle battery is unable to be cooled by a refrigerant due to an insufficient refrigerant amount may be prevented by controlling charging power based on a monitoring result of a current refrigerant amount.

Abstract: Described herein are azetidine and pyrrolidine PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Abstract: A biomass pyrolysis device and a biomass pyrolysis method is for optimal matching of thermal energy and microwave energy, wherein the device comprises a power generation system, a drying device and a microwave pyrolysis device; wherein the drying device is a cylinder nested with a flue gas layer and a material layer, a material inlet of the drying device is connected with a feeding device, and a volatile outlet is connected with a condensing unit; the microwave pyrolysis device is connected with a material outlet of the drying device, and a pyrolysis gas outlet of the microwave pyrolysis device is connected with the condensing unit; the condensing unit is connected with the power generation system, and waste gas generated by the power generation system is introduced into the flue gas layer of the drying device.

Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Abstract: A protein comprising (i) a domain of the Platelet-Derived Growth Factor receptor (PDGFR) and (ii) a domain of the Vascular Endothelial Growth Factor receptor (VEGFR) is provided. In a preferred embodiment, said domain of PDGFR and said domain of VEGFR are attached by a linker consisting of proline, alanine and serine. The domain of PDGFR and said domain of VEGFR can also be attached by a linker consisting of proline and alanine. Compositions comprising the proteins, as well as therapeutic uses thereof are also provided.

Abstract: Described herein are MK2 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of autoimmune disorders, chronic inflammatory disorders, acute inflammatory disorders, auto-inflammatory disorders, fibrotic disorders, metabolic disorders, neoplastic disorders, and cardiovascular or cerebrovascular disorders.

Abstract: An array-spraying additive manufacturing apparatus and method for manufacturing a large-sized equiaxed crystal aluminum alloy ingot, comprising: a liquid aluminum spraying mechanism having array nozzles disposed in an atmospheric pressure chamber, a movable condensing mechanism disposed in the atmospheric pressure chamber below the liquid aluminum spraying mechanism, and a control mechanism. The control mechanism sends an upward guiding command to a release mechanism and issues a three-dimensional movement command to the movable condensing mechanism, such that liquid aluminum in the liquid aluminum spraying mechanism is sprayed at the surface of the movable condensing mechanism in a continuous array of liquid flows according to a preset path and is rapidly condensed to form an ingot. Also disclosed is an additive manufacturing method employing the apparatus.

Abstract: Described herein are PARP1 inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of cancer.

Abstract: Disclosed are compounds of Formula 1, and pharmaceutically acceptable salts thereof, wherein G, L1, L2, R1, R2, R3, and R4 are defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula 1, pharmaceutical compositions containing them, and their use for treating disorders, diseases, and conditions involving the immune system and inflammation, including rheumatoid arthritis, hematological malignancies, epithelial cancers (i.e., carcinomas), and other disorders, diseases, and conditions for which inhibition of SYK is indicated.

Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.

Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.